WolverHeme Happy Hour cover image

Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia

WolverHeme Happy Hour

00:00

The Role of Rituxin in Leukemia Treatment

The GRAL-05 study looked at two different randomizations, one of which was hyper-fractionated cytoxin during induction and late intensification. And they saw a longer event-free survival with Rituximab compared to the control group. But again, probably underpowered. So we see this study, we see that outcomes are improved with addition to Rituxin.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app